[HTML][HTML] Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma
SJ Schuster, SS Neelapu, BL Gause… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2011•ncbi.nlm.nih.gov
Purpose Vaccination with hybridoma-derived autologous tumor immunoglobulin (Ig) idiotype
(Id) conjugated to keyhole limpet hemocyanin (KLH) and administered with granulocyte-
monocyte colony-stimulating factor (GM-CSF) induces follicular lymphoma (FL)–specific
immune responses. To determine the clinical benefit of this vaccine, we conducted a double-
blind multicenter controlled phase III trial.
(Id) conjugated to keyhole limpet hemocyanin (KLH) and administered with granulocyte-
monocyte colony-stimulating factor (GM-CSF) induces follicular lymphoma (FL)–specific
immune responses. To determine the clinical benefit of this vaccine, we conducted a double-
blind multicenter controlled phase III trial.
Abstract
Purpose
Vaccination with hybridoma-derived autologous tumor immunoglobulin (Ig) idiotype (Id) conjugated to keyhole limpet hemocyanin (KLH) and administered with granulocyte-monocyte colony-stimulating factor (GM-CSF) induces follicular lymphoma (FL)–specific immune responses. To determine the clinical benefit of this vaccine, we conducted a double-blind multicenter controlled phase III trial.
ncbi.nlm.nih.gov